Table 3.

Retrospective trials on neuroendocrine tumors (NETs) using peptide receptor radionuclide therapy (PRRT) [84,85,87,89,90,91,92]. PFS = progression-free survival; OS = overall survival.

References	Radio Ligand	Number	PFS (month)	OS (month)
Valkema et al. [89]	90Y-DOTATOC	58	29	37
Kwekkeboom et al. [87]	177Lu-DOTATATE	310	33	46
Bushnell et al. [84]	90Y-DOTATOC	90	16	27
Cwikla et al. [85]	90Y-DOTATATE	58	17	22
Pfeifer et al. [90]	90Y-DOTATOC	53	29	NA
Bodei et al. [91]	177Lu-DOTATATE	39	36	NA
Ezziddin et al. [92]	177Lu-DOTATATE	74	26	55